Clinical Trial

A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-12; most recent amendment 2025-09-28.
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT07124221
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions Hyperprolactinemia
Enrollment 382 participants
Start Date 2025-09-12
Primary Completion 2026-11-21 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-02